basic and diluted 146,296 79,709 123,634 78,672
Biodesix, Inc.
Reconciliation of Net Loss to Adjusted EBITDA (unaudited)
(in thousands)
Three Months Ended Nine Months Ended
September 30, September 30,
--------------------- ---------------------
2024 2023 2024 2023
-------- ---------- -------- ----------
Net loss $(10,258) $ (10,949) $(34,680) $ (43,007)
Interest
expense 2,041 2,386 6,506 7,207
Depreciation
and
amortization 1,492 782 4,324 2,351
Share-based
compensation
expense 1,515 954 5,373 4,292
Loss on
extinguishment
of liabilities -- -- 248 --
COVID-19
Revenue -- -- -- (13)
COVID-19 Direct
costs and
expenses -- -- -- 1
Change in fair
value of
warrant
liability,
net -- 1,393 -- 1,332
Other expense
(income), net (374) (2) 77 (4)
------- --------- ------- ---------
Adjusted EBITDA $ (5,584) $ (5,436) $(18,152) $ (27,841)
======= ========= ======= =========
(END) Dow Jones Newswires
November 01, 2024 06:00 ET (10:00 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.